 |
 |
This is a multi-part message in MIME format. --------------3F3027A238CC Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit -- J. R. Bruman (818) 789-3694 3527 Cody Road Sherman Oaks, CA 91403-5013 --------------3F3027A238CC Content-Type: message/rfc822 Content-Transfer-Encoding: 7bit Content-Disposition: inline Message-ID: <[log in to unmask]> Date: Mon, 16 Nov 1998 22:57:18 -0800 From: "J. R. Bruman" <[log in to unmask]> Reply-To: [log in to unmask] X-Mailer: Mozilla 3.0C-NC320 (Win95; U) MIME-Version: 1.0 To: Parkinson's Information Exchange <[log in to unmask]> Subject: Re: NEWS: FDA warns new PD drug may contribute to liver failure References: <[log in to unmask]> Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit janet paterson wrote: > > FDA warns new Parkinson's drug may contribute to liver failure The news about Tasmar is disappointing, but I enjoy its benefit and should like to continue taking it if it's not withdrawn from sale. The liver damage risk was not unknown; one fatality was reported in the first version of the product information leaflet, but the 3 additional deaths are more worrisome. I started Tasmar in June of this year and recently began the recommended (now required) periodic testing of liver function, supposed to continue for 6 months. Duration of the monitoring period will no doubt be adjusted as experience is gained. To my knowledge only one other COMT inhibitor, entacapone (Comtan) is in the approval process, but it may be less effective than Tasmar, and its adverse side effects, if any, even less known. At my age, my liver probably has already endured a lot of abuse; but I like Tasmar almost as much as I like beer and wine, and would hate to give up either one. Cheers, Joe -- J. R. Bruman (818) 789-3694 3527 Cody Road Sherman Oaks, CA 91403-5013 --------------3F3027A238CC--